Enlivex Therapeutics Ltd. Ordinary Shares
Symbol: ENLV (NASDAQ)
1.08
▲ (1.89%) 0.020
Company Description:
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
Key Stats
- Today's Open: $1.07
- Today's High: $1.08
- Today's Low: $1.05
- Today's Volume: 107.01K
- Yesterday Close: $1.06
- Yesterday High: $1.1
- Yesterday Low: $1.06
- Yesterday Volume: 84.73K
- Last Min Volume: 971
- Last Min High: $1.08
- Last Min Low: $1.08
- Last Min VWAP: $1.08
Company Profile
- Name: Enlivex Therapeutics Ltd. Ordinary Shares
- Website: https://www.enlivex.com
- Listed Date: 2014-07-31
- Location: ,
- Market Status: Active
- CIK Number: 0001596812
- SIC Code:
- SIC description:
- Market Cap: $25.75M
- Round Lot: 100
- Outstanding Shares: 24.29M
- Asset Type: CS
RECENT FILINGS FOR ENLV
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-25 | 6-K | View |
| 2025-09-11 | 6-K | View |
| 2025-09-09 | 6-K | View |
| 2025-08-29 | 6-K | View |
| 2025-08-18 | 6-K | View |
| 2025-08-18 | 6-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | 6-K | View |
| 2025-07-28 | 6-K | View |
| 2025-05-30 | 6-K | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-13 | 424B3 | View |
| 2025-05-12 | EFFECT | View |
| 2025-05-08 | CORRESP | View |
| 2025-05-07 | UPLOAD | View |
| 2025-05-02 | F-3 | View |
| 2025-04-30 | 20-F | View |
| 2025-04-23 | 6-K | View |
| 2025-04-21 | 6-K | View |
| 2025-04-03 | 6-K | View |
Latest News on ENLV